

Mymetics Corporation

Overview

September 2015

Important Notice



This document has been prepared by Mymetics Corporation ("Mymetics" or the "Company") for private circulation only. Mymetics is a public company listed on the OTC QB in the USA under MYMX whose European Executive Office is in Lausanne, Switzerland. This document should not be viewed as an offering circular, private placement memorandum or prospectus and does not constitute an offer, solicitation or invitation by or on behalf of Mymetics to any person to tender for, subscribe for, purchase or invest in any securities or any other investment. By accepting this document, the recipient agrees to keep this document confidential and not to reproduce it in whole or in part or distribute it outside of the firm to which it is provided without the written consent of Mymetics. At the request of Mymetics, the recipient must promptly return the document and all reproductions in whole or in part to Mymetics. The information and opinions contained in this document are for background purposes only and do not purport to be full or complete. It is not intended to provide the basis of any investment or other evaluation and is not and should not be construed as a recommendation or investment advice by Mymetics or any other person that any recipient of the document should make any investment. Mymetics has not independently verified the contents of the document. Accordingly, no representation, warranty or undertaking, express or implied, is made and no responsibility is accepted by Mymetics or any other party as to the accuracy or completeness in any respect of any information contained or statement made herein. All information in this document is subject to change without notice. The delivery of this document at any time does not imply that there has been no change since its date. This presentation includes forward-looking statements that relate to the Company's objectives, estimates and goals. Any statements that are not statements of historical fact should be considered forward-looking statements. The Company's business is subject to numerous risks and uncertainties, including the necessity to conduct further clinical trials and related studies, product testing and regulatory, approval, efficacy and safety. These and other risks and uncertainties could cause the company's actual results and developments to be materially different from those expressed or implied by any of these forward-looking Statements. Please refer to Mymetics' annual report as of December 31, 2014 on Form 10-K to the Securities and Exchange Commission for a full description of the Company's risks and operations. Any sales of the Company's securities pursuant to this confidential document are intended to be in compliance with Regulation S of the US Securities Act of 1933, as amended (the "Act"). It cannot therefore be made available to "US persons" within the meaning of rule 902(k) of the Act. No shares will be sold to US persons as defined above or to any person resident in the United States.

Mymetics' vision is to become leading developer of the new generation of mucosal and virosome based vaccines for infectious diseases

Why Vaccines?



Prevention better than Treatment: Lower Cost of Health Care

Currently only 26 Diseases are Prevented by Vaccines,
Many More to Address and Significant Unmet Needs Remain

Significant Unmet Needs Remain

- 25% of worldwide annual deaths due to infectious disease (15M)²
- Major targets remain: RSV, CMV, HIV, HSV


Novel Vaccine Approaches Required

Market Growth Driven Mainly by Innovation

- Blockbuster premium priced vaccines ¹
 - Prevnar 13[®]: \$5,200M
 - Gardasil[®] & Cervarix[®]: \$2,300M
 - Rotateq[®] & Rotarix[®]: \$1,900M
 - Zostavax[®]: \$ 817M

High Priority Target for Big Pharma

Worldwide Vaccine Sales ³
Growing 2-3x Faster than Drug Sales



¹Peak annual sales per BioPharm Insight; August 8, 2012
²Fauci, et al Emerging Infectious Diseases 11 (4); 2005
³EvaluatePharma database (Defined Health); September 2011

Investment Highlights



- High Growth Vaccine market: \$27.3 Billion in 2012, expected to reach \$48 Billion by 2017 (CAGR 12%)
- Differentiator: Virosome Platform Technology, applicable to broad range of high-value commercial vaccines
- Third Party Validation: Already strong License, Collaboration and Funding Agreements in place with major Pharma and Leading Foundations
- Strong Management Team and access to world class Scientific Advisors
- Strong IP protection with issued patents in all major territories
- Low valuation, Revenue generating, significant upside potential

Mymetics Summary



- Mymetics Corporation:** OTCQB MYMX – Venture Stage market Place and current in SEC reporting
- Location / resources:** HQ in Lausanne, Switzerland and R&D in Leiden, the Netherlands, total of 14 FTEs
- Core Competence:** World leading experts and IP in R&D and CMC for virosomes technology, integration and presentation of membrane proteins for innovative vaccine candidates against life threatening infectious diseases.
- Pipeline:**
- | | |
|-----------------|--|
| Clinical stage: | Intra-nasal Influenza, HIV and Malaria |
| Pre-clinical: | RSV and HSV |
- Objective:** Build small / medium size innovative R&D virosome vaccine company with strong partnerships, Phase II – III clinical vaccine pipeline and have optionality for M&A or sale
- Priorities:** Execute, deliver and expand on existing partnerships
Expand to new partnerships for i.n. influenza and advance new virosome vaccine candidate

Recent Achievements

- **Jan. 2014** - Out-license and collaboration deal for RSV vaccine funded by Astellas. Up to \$82 million in upfront & milestone payments and double digit royalties.
- **Mar. 2014** - Strengthened core virosome platform and know-how. Hired Head of Quality and Manufacturing. Former Head of process development and manufacturing of Pevion Biotech with > 10 years virosome CMC experience.
- **Oct. 2014** - Start of Gates Foundation \$1.8 million funded HIV vaccine study at Texas Biomedical Research Inst.
- **Nov. 2014** - Start of PATH-MVI funded study for transmission blocking malaria vaccine candidate based on virosome technology and antigens from NIAID (LMIV).
- **Apr. 2015** – Mymetics leading consortium awarded €8.4 million in grants from EC (Horizon 2020) and Swiss innovation funds to develop thermostable and cold-chain independent virosome vaccines.



Management Team





- **Ronald Kempers, MSc, CEO – Joined in 2009**
 - Senior business leader & entrepreneur;
 - Over 20 years international business management & finance experience with Fortune 100 companies (Hewlett-Packard, Oracle) and healthcare start-ups;
 - MSc in Business Administration Erasmus University Rotterdam and IMD, Lausanne.
- **Toon Stegmann, Ph.D., CSO Netherlands & Head Virosome R&D - Joined in 2009**
 - Original inventor & leading virosome expert;
 - Co-Founded Mymetics BV; Dir Vaccine Research Algonomics & Crucell;
 - Prof. Biochemistry & Molecular Biology Univ of Toulouse; Asst. Prof. Biochemistry, Univ of Basel
 - >50 papers; 12 books.
- **Sylvain Fleury, Ph.D., CSO – Joined in 2003**
 - 20 years in pharmaceutical industry collaborations (Genentech, Roche & Novartis) and public research institutions (Clinical Research Institute of Montreal, Columbia Hospital in NY, NIH in Bethesda, CHUV in Lausanne) in infectious diseases & gene therapy;
 - Manager of various pre-clinical & clinical trials with antiviral drugs and virosome-based vaccines;
 - Expertise in Immunology, Immunotherapy, antigen & vaccine design. Numerous publications in high impact leading journals.
- **Mario Amacker, Ph.D. - Head Manufacturing and Quality – Joined in 2014**
 - Senior CMC virosome vaccine development manager with a track record of successfully driving vaccine development projects through early phases of development (preclinical, clinical phases I-II).
 - More than 10 years of hands-on experience in process development, virosome vaccine manufacturing and quality control, project management and quality assurance.

Virosomes


- Virosomes are virus-like particles consisting of virus envelopes
- Virosomes lack the genetic material of the native virus: **virosomes are non-infectious**
- Retain the **receptor-binding** and **membrane fusion** properties of the virus
- Lipid membrane allows **optimal presentation and folding of antigens**



virus




virosome vaccine



virosome as carrier platform
for vaccines

Creating Virosomes



Advantages Virosome Platform



SAFETY:	No Genetic Material – Non Infectious
IMMUNOGENICITY:	Stay close to Nature by Reconstituting the Natural Viral Membrane Includes Natural Proteins of Virus Possibility to include Antigens and Adjuvants in Membrane Optimal Presentation to Immune System Strong Induction of Systemic (blood) & Mucosal Immunity
BROADLY APPLICABLE:	For any Enveloped Virus and as Antigen Delivery System
SCALABLE & COST:	Large Scale and GMP enabled and low COGS
ALREADY PROVEN:	Epaxal [®] (Hep A) & Inflexal [®] (flu) – JNJ; Invivac [®] - Abbott (flu)

Virosome Vaccines: The Safety of Killed Virus with the Immune Response of a Live Virus

Product Pipeline



Product	Discovery	Pre-Clinical	Phase I	Phase II	Phase III	Virosome basis	Partners
RSV Prophylactic	Completed					RSV virus adjuvant	Astellas / ClearPath
HSV 1 + 2	Completed					HSV virus adjuvant	
Intranasal Influenza Prophylactic	Completed					Influenza virus	
HIV-1 Prophylactic	Completed					Influenza virus + HIV antigens	B & M Gates Foundation
Malaria Prophylactic	Completed					Influenza virus + malaria antigens	PATH-MVI

Summary of Pipeline results

RSV vaccine:

- Strong RSV pre-clinical results: protection & absence of enhanced disease in cotton rats and mice.
- Publications: Vaccine, Jun. 2010.; PlosOne, May 2012; Vaccine, Feb. 2013

Jan. 2014: License and Collaboration Agreement w. Astellas Pharma – ClearPath

Intranasal Flu vaccine: Solvay / Abbott finished successfully a Phase I clinical trial with 100 people meeting / exceeding all EU (CHMP) criteria for injected influenza vaccines.

HIV vaccine: offering both blood and mucosal antibodies for optimal prevention of HIV-I mucosal transmission

- 100% protection in macaque monkeys against multiple heterologous virus challenges
- HIV Phase I proof-of-concept: strong safety and tolerance profile and presence of antibodies in mucosal secretions;
- Publications: Immunity, Feb. 2011; PlosOne, Feb. 2013.

Oct. 2014: Start of Bill & Melinda Gates Foundation NHP study with Texas Biomed.

Malaria vaccine: Finished successfully Phase Ib on children in Tanzania (semi immune people). Strong safety and tolerance profile. Antibody presence upto 360 days & 50% lower attack rate.

Nov. 2014: Start of PATH MVI funded study for transmission blocking virosome vaccine candidates with LMIV (NIAID)

HSV vaccine: Preclinical data, i.n. and i.m. vaccination of mice: neutralizing antibodies

Financial Summary



- OTC QB: MYMX – current in SEC reporting and filings but not leveraged public listing until now
- 300 million shares outstanding, public float around 25%
- Recent stock price: 0.02 to 0.05 USD per share with very limited liquidity
- Capital Raised last 6 years: \$25 million in equity; \$35 million in convertible debt through private funding
- 55% of Company held by executives / board members
- Since September 2013 revenue generating and low cash burn

Summary



- Unique vaccine technology, know-how and IP: virosome as antigen carrier
- World leading virosome and membrane protein expertise and know-how
- Attractive and diverse pipeline with excellent results to date
- Out-licensing and collaboration agreement with leading Pharma for block buster RSV vaccine candidate
- Obtained non-dilutive funding from Gates Foundation and PATH MVI for HIV and malaria vaccine development
- Revenue generating since Sep 2013
- Strong Management and Scientific Advisory Board
- Provides access to rapidly growing, high margin vaccine sector